V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220019865 | 220009180 | 1.8 | 70 | null | null | 2013-12-02 | BUSULFAN + FLUDARABINE | N | null | 220034562 | CYTARABINE IT + METHOTREXATE |
| 220019866 | 220009182 | null | 0 | Curative (C) | 2014-07-17 | 2015-07-13 | QUASAR 2 TRIAL | N | N | 220034567 | MITOXANTRONE + TRETINOIN |
| 220019867 | 220009184 | null | null | Palliative (P) | 2016-06-14 | 2016-06-14 | BORTEZOMIB + THALIDOMIDE | N | N | 220034571 | SPANISH MAINTENANCE |
| 220019868 | 220009194 | 1.79 | 93.6 | Curative (C) | 2016-06-09 | 2016-07-02 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 220034611 | CISPLATIN + ETOPOSIDE |
| 220019869 | 220009195 | 1.64 | 0 | Curative (C) | 2017-01-20 | 2017-10-25 | MERCAPTOPURINE + METHOTREXATE | N | N | 220034611 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 220019870 | 220022114 | 1.88 | 82 | Curative (C) | 2018-03-10 | 2018-03-10 | Carboplatin AUC 6 - 10 | N | N | 220034615 | CARBOPLATIN + VINORELBINE |
| 220019871 | 220014898 | 1.8 | 80.4 | Curative (C) | 2018-03-24 | 2018-03-29 | CODOX M | N | N | 220034662 | INTERFERON |
| 220019872 | 220009207 | 1.65 | 81.7 | null | 2013-12-21 | 2013-12-23 | CLADRIBINE + CYTARABINE + DAUNORUBICIN | N | N | 220034670 | CISPLATIN + ETOPOSIDE |
| 220019873 | 220009213 | null | null | Curative (C) | 2017-10-21 | 2017-10-26 | ALL UKALL2011 Ind A Sht Dex (PAsp) | Y | null | 220034678 | IBRUTINIB |
| 220019874 | 220014904 | null | null | Palliative (P) | 2017-04-09 | 2017-06-26 | TIP | N | N | 220034686 | GEMCITABINE + OXALIPLATIN + PACLITAXEL |
| 220019875 | 220014905 | 1.67 | 89.6 | Curative (C) | 2016-04-22 | 2016-05-14 | TRASTUZUMAB | N | N | 220034690 | CAPECITABINE + IRINOTECAN |
| 220019876 | 220009223 | 1.72 | 94.4 | Curative (C) | null | 2013-08-01 | ALL UKALL60+ TRIAL | 02 | N | 220034697 | FIGARO TRIAL |
| 220019877 | 220009232 | 1.7 | null | Curative (C) | 2017-01-04 | 2017-01-04 | Bevacizumab + Cape + Oxali 21day | N | null | 220034742 | MITOXANTRONE + TRETINOIN |
| 220019878 | 220009239 | 1.67 | 80 | Curative (C) | 2014-10-29 | 2014-12-08 | Arsenic Trioxide (consolidation) | null | N | 220034796 | DACTINOMYCIN |
| 220019879 | 220009242 | 1.51 | null | Palliative (P) | 2014-01-28 | 2014-04-15 | Cetuximab+Cisplatin+FU (> Cycle 2) | 02 | N | 220034799 | DABRAFENIB + TRAMETINIB |
| 220019880 | 220009244 | 1.78 | 98.15 | Curative (C) | 2015-03-26 | 2015-12-03 | Capecitabine + Oxaliplatin 21day | Y | N | 220034800 | BUSULPHAN |
| 220019881 | 220014917 | 1.56 | 85.7 | Curative (C) | 2015-01-28 | 2015-01-28 | GDCVP | 02 | N | 220034818 | MACE |
| 220019882 | 220009249 | 1.62 | 72.8 | Disease modification (D) | 2016-02-28 | 2016-02-28 | Capecitabine (21days) + Carboplatin | 02 | Y | 220034834 | DOCETAXEL + TRASTUZUMAB |
| 220019883 | 220018143 | 0 | 78.3 | Adjuvant (A) | 2016-05-08 | 2017-01-06 | CAMELLIA Trial | 02 | N | 220034845 | CAPECITABINE |
| 220019884 | 220009263 | 1.7 | 94.15 | Curative (C) | 2016-04-22 | 2016-12-01 | BUSULFAN + CYCLO | N | null | 220034933 | BEAM |
| 220019885 | 220009265 | 1.66 | 72.1 | Disease modification (D) | null | 2015-05-10 | Carboplatin AUC 6 - 10 | 02 | N | 220034935 | IPM |
| 220019886 | 220009275 | 0 | 77 | Disease modification (D) | 2017-09-09 | 2017-09-15 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE | N | N | 220035062 | CAPECITABINE + IRINOTECAN |
| 220019887 | 220009278 | 1.71 | 67.3 | Palliative (P) | 2016-06-22 | 2016-11-03 | Busulfan po + Fludarabine RIC Allo | N | N | 220035065 | DOCETAXEL + GEMCITABINE |
| 220019890 | 220018155 | null | 119.4 | Curative (C) | 2015-01-27 | 2015-01-31 | BUSULFAN + FLUDARABINE | N | N | 220035113 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN |
| 220019891 | 220009301 | null | null | Palliative (P) | 2017-04-06 | 2017-04-19 | MITOXANTRONE + TRETINOIN | N | N | 220035146 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220019892 | 220009305 | null | 83 | null | 2017-12-03 | 2018-02-09 | MELPHALAN | N | null | 220035152 | MELPHALAN |
| 220019893 | 220009313 | null | null | Palliative (P) | 2018-01-15 | 2018-03-19 | Capecitabine | N | null | 220035189 | SORAFENIB |
| 220019894 | 220009318 | 1.66 | null | Curative (C) | 2017-01-21 | 2017-03-13 | Arsenic trioxide | N | N | 220035190 | ARSENIC TRIOXIDE + ATRA |
| 220019895 | 220009323 | 1.76 | 96 | null | 2015-09-15 | 2015-09-27 | ALL UKALL2011 IndB Std Dex (PegAsp) | 02 | N | 220035212 | ETOPOSIDE |
| 220019896 | 220009324 | 1.68 | 87.2 | Curative (C) | 2014-04-26 | 2014-04-26 | CYTARABINE + FLUDARABINE | 2 | N | 220035219 | MERCAPTOPURINE |
| 220019897 | 220009326 | 1.74 | 73.4 | Disease modification (D) | 2018-08-29 | 2018-08-29 | CAV | 01 | N | 220035229 | CISPLATIN + FLUOROURACIL |
| 220019898 | 220018160 | 1.63 | 52 | Disease modification (D) | 2017-07-09 | 2017-08-09 | CETUXIMAB | N | null | 220035232 | MITOXANTRONE + TRETINOIN |
| 220019899 | 220009332 | 1.81 | 53 | Curative (C) | 2015-09-23 | 2015-09-29 | Cetuximab + Radiotherapy Maint | N | null | 220035243 | PEMBROLIZUMAB |
| 220019900 | 220009340 | 1.69 | 83 | Curative (C) | 2014-08-28 | 2014-08-28 | IPM | 02 | N | 220035299 | CAMELLIA TRIAL |
| 220019901 | 220021920 | 1.77 | 94.2 | Palliative (P) | 2016-10-17 | 2019-02-09 | IPILIMUMAB + NIVOLUMAB | N | null | 220035316 | ARSENIC TRIOXIDE + ATRA |
| 220019902 | 220009346 | 1.45 | 69.4 | Curative (C) | 2014-01-01 | 2015-03-14 | Alemtuzumab+Busulfan+CyclophosphMUD | 2 | N | 220035329 | BUSULPHAN + CYCLO |
| 220019903 | 220014960 | null | null | Not known (9) | null | 2013-12-31 | OCTREOTIDE | null | null | 220035332 | CISPLATIN + RT |
| 220019904 | 220009351 | 1.73 | 78.4 | Curative (C) | 2013-01-19 | 2013-04-03 | Bendamustine+Rituximab(Sub Courses) | N | N | 220035347 | GCLAC |
| 220019907 | 220009359 | 1.49 | 73 | Palliative (P) | 2017-08-08 | 2017-12-31 | PEMBROLIZUMAB | N | N | 220035373 | SUNITINIB |
| 220019908 | 220009363 | 1.82 | 115.1 | Curative (C) | 2017-12-20 | 2017-12-27 | BUSULFAN + MELPHALAN | 02 | N | 220035392 | THALIDOMIDE |
| 220019909 | 220014970 | 1.85 | 105 | Not known (9) | 2013-08-29 | 2013-08-30 | FIGARO TRIAL | 2 | N | 220035399 | PEMBROLIZUMAB |
| 220019910 | 220009367 | 1.54 | 60.8 | null | 2016-02-19 | 2016-02-19 | IBRUTINIB | N | N | 220035401 | BUSULFAN + FLUDARABINE + METHOTREXATE |
| 220019911 | 220009368 | null | 68.3 | Palliative (P) | 2017-02-14 | 2017-02-14 | Cytarabine+Methotrexate Intrathecal | 02 | N | 220035406 | METHOTREXATE + PEGASPARGASE |
| 220019912 | 220009371 | 1.76 | 107.8 | Curative (C) | 2014-12-10 | 2016-04-15 | Doxorubin 50mg/m2 | 2 | null | 220035412 | VINORELBINE |
| 220019913 | 220009378 | 1.77 | 74.4 | null | 2013-12-20 | 2014-03-11 | TRASTUZUMAB | N | N | 220035414 | TRASTUZUMAB |
| 220019914 | 220014975 | 1.64 | 57 | Curative (C) | 2018-09-27 | 2018-10-02 | VINORELBINE | N | N | 220035428 | VINORELBINE |
| 220019916 | 220009386 | null | 59.8 | Palliative (P) | 2018-05-26 | 2018-05-26 | CHOP R - 21 days | null | null | 220035451 | MERCAPTOPURINE |
| 220019917 | 220014978 | 1.75 | null | Palliative (P) | 2017-08-13 | 2017-08-18 | Busulfan po + Fludarabine RIC Allo | N | N | 220035454 | METHOTREXATE HIGH DOSE |
| 220019919 | 220022116 | null | null | Palliative (P) | 2014-05-19 | 2014-06-27 | Alemtuzumab+Busulfan+CyclophosphMUD | N | null | 220035488 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220019920 | 220009397 | 1.65 | 47 | Palliative (P) | null | 2014-05-07 | Cytarabine+Methotrexate Intrathecal | N | N | 220035497 | MIDAC |